Life Science Investing Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Life Science Investing Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Life Science Investing Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Life Science Investing Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
